Antioxidants in Age-Related Macular Degeneration: Lights and Shadows

Antioxidants, Journal Year: 2025, Volume and Issue: 14(2), P. 152 - 152

Published: Jan. 27, 2025

Age-related macular degeneration (AMD) is a leading cause of vision impairment worldwide, primarily driven by oxidative stress and inflammation. This review examines the role antioxidants in mitigating damage, emphasizing both their therapeutic potential limitations AMD management. Key findings underscore efficacy specific antioxidants, including vitamins C E, lutein, zeaxanthin, Coenzyme Q10, slowing progression. Landmark studies such as AREDS AREDS2 have shaped current antioxidant formulations, although challenges persist, patient variability long-term safety concerns. Emerging therapies, mitochondrial-targeted novel compounds like saffron resveratrol, offer promising avenues for treatment. Complementary lifestyle interventions, antioxidant-rich diets physical activity, further support holistic management approaches. highlights critical therapy, advocating personalized strategies to optimize outcomes.

Language: Английский

---

The Effect of a specific Vitamin Supplement containing L-methylfolate (Ocufolin forte) in Patients with Neovascular Age-Related Macular Degeneration

Advances in Ophthalmology Practice and Research, Journal Year: 2025, Volume and Issue: 5(2), P. 135 - 141

Published: March 4, 2025

Patients with nAMD often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to anti-VEGF therapy reduces these two risk factors favorably influences disease course. A total 27 eyes/27 patients intra- subretinal fluid, Hcy above 12 ​μmol/L, RVP at least 8 ​mm IOP, IOP between 10 20 ​mmHg were included in this study. All eyes received three injections 0.05 ​ml aflibercept one-month intervals clinically indicated. Fifteen additionally one capsule Ocufolin forte per day group, OG), other twelve served control group (control CG). The following measured before four months later: blood Hcy, best-corrected visual acuity (BCVA), intra-ocular (IOP), RVP, optical coherence tomography (OCT), - angiography (OCTA). decreased on average by 5.58 ​μmol/L OG 0.57 CG. 4.60 0.75 difference groups was significant for both parameters (P ​<0.001); 66% 41% CG had no fluid end After completion study, injection could be extended more than patients. When added standard therapy, reduced significantly greater extent without forte. In addition, positive influence morphology future treatment therapy.

Language: Английский

---

Tyrosol protects RPE cells from H2O2-induced oxidative damage in vitro and in vivo through activation of the Nrf2/HO-1 pathway

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177316 - 177316

Published: Jan. 1, 2025

Language: Английский

---

Evidence for a Functional Link Between the Nrf2 Signalling Pathway and Cytoprotective Effect of S-Petasin in Human Retinal Pigment Epithelium Cells Exposed to Oxidative Stress

Antioxidants, Journal Year: 2025, Volume and Issue: 14(2), P. 180 - 180

Published: Feb. 4, 2025

The retinal pigment epithelium (RPE) is a highly specialised monolayer subjected to constant oxidative stress, which, in the long term, favours development of complex pathological process that underlying cause macular damage. Therefore, counteracting overproduction ROS best-researched approach preserve functional integrity RPE. S-Petasin, secondary metabolite extracted from plant Petasites hybridus, has numerous biological effects, which highlight its anti-inflammatory and antioxidative properties. aim our study investigate whether S-Petasin exerts cytoprotective effects by protecting RPE pretreatment with were assessed determination cell viability, intracellular levels, activation Nrf2 pathway resulting post-transcriptional antioxidant/antiapoptotic response. Our results show (1) reduces improving viability exposed damage; (2) activates signalling pathway, modulating response antioxidant chemical biomarkers; (3) Bax an increase those Bcl-2, concomitant downregulation Bax/Bc-2 ratio. Overall, provide first evidence able protect

Language: Английский

---

Clinical Applications of the Cone Contrast Test in Ophthalmology and Neurology

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 3079 - 3079

Published: April 29, 2025

Color vision is a critical aspect of human visual perception, yet traditional assessments often lack quantitative precision. The Rabin Cone Contrast Test and its successors offer objective, standardized measurements cone-specific contrast sensitivity. These tests improve the detection classification color deficiencies can facilitate monitoring deficits in inherited retinal diseases, cone dystrophies, optic neuropathies, brain injuries. Integrating testing into clinical practice presents more reliable, reproducible, functionally relevant evaluation, highlighting value disease diagnosis, characterization, management.

Language: Английский

---

Exosome Innovations in Ophthalmology and Sjögren’s Syndrome

Advances in experimental medicine and biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---